1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 CAR T-cell Therapy
1.2.3 TCR T-cell Therapy
1.3 Market by Application
1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2017-2028)
2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Region
2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2017-2022)
2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2023-2028)
2.3 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
2.3.1 Gene Modifying Immunotherapy for Blood Cancer Industry Trends
2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue
3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2017-2022)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2017-2022)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021
3.5 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
3.6 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
3.7 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2017-2022)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2023-2028)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2017-2022)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
8.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
8.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
9.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
9.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
10.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
10.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.1.5 Novartis Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Detail
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.2.5 Kite Pharma Recent Development
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Detail
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.3.5 Juno Therapeutics Recent Development
11.4 Cellectis
11.4.1 Cellectis Company Detail
11.4.2 Cellectis Business Overview
11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.4.5 Cellectis Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Detail
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.5.5 Ziopharm Oncology Recent Development
11.6 Celyad
11.6.1 Celyad Company Detail
11.6.2 Celyad Business Overview
11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.6.5 Celyad Recent Development
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Detail
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.7.5 Bluebird Bio Recent Development
11.8 Bellicum Pharmaceuticals
11.8.1 Bellicum Pharmaceuticals Company Detail
11.8.2 Bellicum Pharmaceuticals Business Overview
11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.8.5 Bellicum Pharmaceuticals Recent Development
11.9 Mustang Bio
11.9.1 Mustang Bio Company Detail
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
11.9.5 Mustang Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
